Minocycline
Minocycline is a highly lipophilic, second-generation **tetracycline antibiotic**. It is notable for its excellent tissue penetration, including crossing the blood-brain barrier and entering the prostate. - **Clinical Uses:** Brucellosis, Lyme disease, hemotropic mycoplasmosis, atypical mycobacterial infections, and resistant nosocomial infections. - **Advantages:** Less likely to cause bone and teeth abnormalities compared to older, more water-soluble tetracyclines. It can be safely used in patients with moderate renal insufficiency without dosage adjustment. - **Additional Properties:** Beyond antimicrobial effects, minocycline exhibits **anti-inflammatory** and **neuroprotective** properties (e.g., inhibition of matrix metalloproteinases), which has led to its investigation as an adjunctive therapy for conditions like hemangiosarcoma, though early results have been disappointing.
กลไกการออกฤทธิ์: Minocycline is a **bacteriostatic** antibiotic that exhibits time-dependent (AUC/MIC) inhibition of bacterial growth. - **Primary Mechanism:** Reversibly binds to the **30S ribosomal subunit** of susceptible organisms → blocks the binding of aminoacyl transfer-RNA to the mRNA-ribosome complex → **inhibits bacterial protein synthesis**. - **Secondary Mechanism:** Reversibly binds to the **50S ribosomal subunit** → alters cytoplasmic membrane permeability, leading to leakage of intracellular components. - **Mammalian Effects:** At very high concentrations, it can inhibit mammalian protein synthesis. It also inhibits **matrix metalloproteinases (MMPs)** and apoptosis, contributing to its anti-inflammatory and neuroprotective effects.
ขนาดยาตามชนิดสัตว์
- Hemotropic mycoplasmosis · 6-11 mg/kg PO q12h · PO · q12h · 21 days
- Adjunctive treatment atypical mycobacterial dermal infections · 5-12.5 mg/kg PO, IV q12h · PO, IV · q12h
- Adjunctive treatment of Nocardiosis, Actinomycosis · 5-25 mg/kg PO, IV q12h · PO, IV · q12h
- Susceptible mycobacterial, L-Forms, or mycoplasma infections · 5-12.5 mg/kg PO q12h · PO · q12h
- Bacterial, rickettsial, mycoplasmal and chlamydial diseases · 5-10 mg/kg · PO · q12h · Avoid dry pilling; follow with a water bolus.
- Susceptible soft tissue and urinary tract infections · 5-12 mg/kg PO or IV q12h · PO, IV · q12h · 7-14 days
- Brucellosis · 25 mg/kg PO once daily (q24h) · PO · q24h · 4 weeks · Given with Gentamicin 5 mg/kg SC once daily for 7 days (weeks 1 and 4). Doxycycline can eventually be substituted. May need two or more 4-week courses.
- Adjunctive treatment of Nocardiosis, Actinomycosis · 5-25 mg/kg PO, IV q12h · PO, IV · q12h
- Brucellosis in animals that are housed singly and neutered · 25 mg/kg PO once daily · PO · q24h · 14 days · Given with dihydrostreptomycin at 5 mg/kg IM twice daily for 7 days.
- Ehrlichiosis (E. canis) · 10 mg/kg PO (rarely IV) q12h · PO, IV · q12h · 28 days · For dogs with a positive test result and clinical signs consistent with the infection.
วิธีการให้ยา
ข้อห้ามใช้
- Hypersensitivity to tetracyclines
- Pregnant or nursing animals
- Animals less than 6 months old (relative contraindication)
- Pregnancy
- Young, developing animals
อาการไม่พึงประสงค์
- Nausea and vomiting (most common)
- Dental or bone staining (if exposed in utero or early life)
- Increases in hepatic enzymes (rare)
- Ototoxicity (rare)
- Urticaria, shivering, hypotension, dyspnea, cardiac arrhythmias, and shock (if given rapidly IV)
- Superinfections (overgrowth of non-susceptible bacteria or fungi)
- Photosensitivity (reported in humans)
- Hepatotoxicity or blood dyscrasias (rare, reported in humans)
- CNS effects like dizziness/lightheadedness (reported in humans)
- Blue-gray pigmentation of skin and mucous membranes (reported in humans)
- Nausea
- Vomiting
- Diarrhoea
- Bone and teeth abnormalities (in developing animals)
- Oesophageal erosions (especially in cats if dry-pilled)
อันตรกิริยาระหว่างยา
- Antacids, Oral (Aluminum, Calcium, Magnesium, Zinc, Bismuth) · Can chelate divalent or trivalent cations, decreasing absorption of the tetracycline. Give at least 12 hours before or after the cation-containing product.
- Bismuth subsalicylate, Kaolin, Pectin · May reduce minocycline absorption.
- Iron, Oral · Decreased tetracycline absorption. Give iron salts 3 hours before or 2 hours after the tetracycline dose.
- Isotretinoin · May increase the risk for nervous system effects when used concurrently.
- Penicillins, Cephalosporins, Aminoglycosides · Bacteriostatic drugs may interfere with the bactericidal activity of these antibiotics (clinical significance is controversial).
- Warfarin · Tetracyclines may depress plasma prothrombin activity; anticoagulant dosage adjustment may be needed.
- Antacids · Reduced absorption of minocycline · moderate
- Calcium salts · Reduced absorption of minocycline · moderate
- Magnesium salts · Reduced absorption of minocycline · moderate
- Iron salts · Reduced absorption of minocycline · moderate
- Sucralfate · Reduced absorption of minocycline · moderate
- Phenobarbital · Increased metabolism of minocycline, decreasing plasma levels · moderate
การติดตาม
- Clinical efficacy (resolution of infection)
- Adverse effects (GI upset, signs of hypersensitivity)
- Renal function (if used concurrently with nephrotoxic drugs like gentamicin)
- Clinical efficacy
- Gastrointestinal signs
- Hepatic function (in patients with pre-existing liver disease)
การได้รับยาเกินขนาด
Oral overdoses are most likely associated with **GI disturbances** (vomiting, anorexia, and/or diarrhea). - **Treatment:** Although less vulnerable to chelation than other tetracyclines, oral administration of divalent or trivalent cation antacids may bind some of the drug and reduce GI distress. - **Supportive Care:** Should the patient develop severe emesis or diarrhea, monitor fluids and electrolytes and replace if necessary.
ข้อมูลอ้างอิงยาของ VetSheet มีไว้สำหรับสัตวแพทย์ผู้มีใบอนุญาตเพื่อช่วยในการตัดสินใจทางคลินิก ไม่ใช่สิ่งทดแทนการวินิจฉัยของผู้เชี่ยวชาญหรือฉลากล่าสุดของผู้ผลิต